Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypophosphatemia associated with coma.

J L Lee, W J Sibbald, R L Holliday

    Canadian Medical Association Journal
    |July 22, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

    ESMO open·2026
    Same author

    Does robotic circumferential oversewing reduce anastomotic leakage in stapled anastomosis for rectal cancer surgery?

    Techniques in coloproctology·2025
    Same author

    Mercury concentrations in historic autopsies from Grassy Narrows First Nation.

    Journal of the neurological sciences·2025
    Same author

    Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Corrigendum to "Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18": [ESMO Open 8 (2023) 101588].

    ESMO open·2024
    Same author

    Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.

    ESMO open·2023

    Severe hypophosphatemia can cause profound coma in critically ill patients. Prompt recognition and intravenous phosphate therapy can improve neurological status, highlighting the need for early intervention.

    Area of Science:

    • Critical Care Medicine
    • Neurology
    • Endocrinology

    Background:

    • Severe hypophosphatemia is a critical electrolyte imbalance.
    • It can lead to severe neurological complications.
    • Risk factors include aggressive intravenous fluid and glucose administration.

    Observation:

    • Three cases of profound coma associated with severe hypophosphatemia are presented.
    • Patients had concurrent conditions such as liver disease or hypothermia.
    • Hypophosphatemia onset coincided with high rates of intravenous glucose and water infusion.

    Findings:

    • Two of the three patients experienced neurological improvement following intravenous phosphate therapy.
    • This suggests a direct link between phosphate levels and neurological function.

    Related Experiment Videos

    Implications:

    • Early recognition and treatment of severe hypophosphatemia are crucial in critically ill patients.
    • Monitoring phosphate levels in vulnerable populations is essential.
    • Intravenous phosphate therapy is a viable treatment for associated coma.